Trevena Company Profile (NASDAQ:TRVN)

Analyst Ratings

Consensus Ratings for Trevena (NASDAQ:TRVN) (?)
Ratings Breakdown: 10 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.22 (133.83% upside)

Analysts' Ratings History for Trevena (NASDAQ:TRVN)
Show:
DateFirmActionRatingPrice TargetActions
6/2/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016WedbushReiterated RatingOutperform$20.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016Needham & Company LLCReiterated RatingBuy$14.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016FBR & CoBoost Price TargetOutperform$13.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$21.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016WallachBeth CapitalInitiated CoverageBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Barclays PLCLower Price TargetOverweight$18.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016Jefferies GroupReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Trevena (NASDAQ:TRVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/5/2016Q1($0.32)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.26)($0.30)$1.64 million$1.88 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q3($0.34)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.37)($0.28)$1.88 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.33)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2015Q414($0.39)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314($0.45)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.35)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q114($0.36)($0.59)$0.03 million$0.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Trevena (NASDAQ:TRVN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($0.33)($0.24)($0.29)
Q2 20165($0.38)($0.27)($0.33)
Q3 20164($0.39)$0.44($0.14)
Q4 20165($0.47)($0.26)($0.33)
Q1 20171($0.53)($0.53)($0.53)
Q2 20171($0.54)($0.54)($0.54)
Q3 20171($0.52)($0.52)($0.52)
Q4 20171($0.57)($0.57)($0.57)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Trevena (NASDAQ:TRVN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Trevena (NASDAQ:TRVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/27/2016Maxine GowenCEOBuy22,084$7.12$157,238.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2015David SoergelCMOSell27,217$10.55$287,139.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014John M LimongelliVPBuy3,000$4.14$12,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Enterprise Associates 12 NewMajor ShareholderBuy1,000,000$4.00$4,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Maxine GowenCEOBuy8,000$4.00$32,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Michael R DoughertyDirectorBuy7,000$4.00$28,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Michael W LarkVPBuy5,000$4.00$20,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Roberto CucaCFOBuy25,000$4.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Leon O Moulder JrDirectorBuy30,200$3.96$119,592.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Rosamond DeeganSVPSell44$7.00$308.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Laboratories Holdings L ForestMajor ShareholderBuy428,571$7.00$2,999,997.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Trevena (NASDAQ:TRVN)
DateHeadline
07/23/16 10:40 AMEquity Roundup: Stock Performance Focus on Trevena, Inc. (NASDAQ:TRVN) - Press Telegraph
07/22/16 09:50 AMDoes Trevena Inc Have Any Gas After Today's Huge Increase? - Consumer Eagle
07/20/16 07:57 PMTrevena, Inc. (NASDAQ:TRVN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/19/16 07:53 AMHow Analysts Feel About Trevena Inc (NASDAQ:TRVN)? - Consumer Eagle
07/16/16 10:03 AMShares Experiencing a Downtrend: Trevena, Inc. (NASDAQ:TRVN) - TGP
07/16/16 10:03 AMBroker Outlook For Trevena Inc (NASDAQ:TRVN) - Fiscal Standard
07/15/16 12:12 PMTrevena Inc Realized Volatility Hits Extreme Level - CML News
07/14/16 07:09 PMTrevena Inc Stock Price Declines Today - Consumer Eagle
07/14/16 07:09 PMEye on Stock Volatility for: Trevena, Inc. (NASDAQ:TRVN) - Engelwood Daily
07/14/16 07:09 PMInsiders Increasing Positions in: Trevena, Inc. (NASDAQ:TRVN) - Press Telegraph
07/11/16 06:48 PMWall Street Ratings and Target Price Views on Trevena, Inc. (NASDAQ:TRVN) - Telanagana Press
07/11/16 06:48 PMHow Many Trevena Inc (NASDAQ:TRVN)'s Analysts Are Bearish? - Engelwood Daily
07/06/16 07:22 PMStock Tracking Down This Month; Investor Alert on Trevena, Inc. (NASDAQ:TRVN) - Engelwood Daily
07/06/16 07:22 PMWill Trevena, Inc. (NASDAQ:TRVN) Surprise Analysts? - Investor Newswire
07/05/16 07:52 AMHow Analysts Feel About Trevena Inc (NASDAQ:TRVN)? - Press Telegraph
07/05/16 07:47 AMTrevena Inc (NASDAQ:TRVN) Broker Price Targets For The Coming Week - Fiscal Standard
07/05/16 07:22 AMThese 3 Biotech Stocks Are Ridiculously Cheap Now -
06/28/16 06:49 PMCovering the Bases on Trevena, Inc. (NASDAQ:TRVN): Where is the Stock Going? - Press Telegraph
06/28/16 10:07 AM3 Growth Stocks to Buy in July -
06/24/16 09:28 AMTrevena, Inc. (NASDAQ:TRVN) Surged 8.86% Afterhours: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ... - KC Register
06/23/16 07:40 PMTrevena, Inc. (NASDAQ:TRVN) Stock Momentum Hits EXTREME Weakness - CML News
06/22/16 08:00 AMBiotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
06/22/16 08:00 AMAnthera Pharmaceuticals : Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
06/17/16 06:00 AMAllergan Carves Middle Path In R&D Spending With 'Open Science' -
06/16/16 03:49 PM6/16/16 - Trevena to Present at the JMP Life Sciences Conference - [at noodls] - Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that its chief ...
06/16/16 03:01 PMTrevena to Present at the JMP Life Sciences Conference - [Business Wire] - Trevena, Inc. , a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that its chief medical officer, David Soergel, M.D., will present a company overview at the JMP Life Sciences Conference on June 21st at 2:00p.m.
06/09/16 07:27 PMTrevena Inc (NASDAQ:TRVN) Just Got Its Billion Dollar Pain Management Bid Underway - Market Exclusive
06/09/16 10:00 AMTrevena Inc (TRVN) Just Got Its Billion Dollar Pain Management Bid Underway - Insider Monkey (blog)
06/09/16 09:34 AMTrevena Inc (TRVN) Just Got Its Billion Dollar Pain Management Bid Underway -
06/08/16 11:15 AMKing of Prussia firm begins late-stage testing of new type of pain medicine -
06/08/16 10:02 AMTrevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of ... - Business Wire (press release)
06/08/16 08:18 AM6/8/16 - Trevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain - [at noodls] - - Trials include comparisons of efficacy, safety and tolerability of oliceridine to both placebo and morphine - - Top-line data for both studies expected in 1Q 2017 - Trevena, Inc. (NASDAQ: TRVN), a clinical ...
06/08/16 06:00 AMTrevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain - [Business Wire] - Trevena, Inc. , a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced the enrollment of the first patients in the Phase 3 APOLLO-1 and APOLLO-2 studies of oliceridine in patients suffering moderate to severe acute pain following bunionectomy and abdominoplasty, respectively.
06/05/16 09:36 AMPortfolio Of Healthcare Movers: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) , Trevena, Inc. (NASDAQ:TRVN) - Is stories
06/03/16 07:38 PMCowen and Company Reiterates Buy Rating for Trevena Inc (TRVN) - Let Me Know About This
06/02/16 07:10 AMTrevena, Inc. breached its 50 day moving average in a Bullish Manner : TRVN-US : June 2, 2016 -
06/01/16 03:01 PMTrevena to Present at the Jefferies 2016 Healthcare Conference - [Business Wire] - Trevena, Inc. , a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that chief executive officer Maxine Gowen, Ph.D., will present a company overview at the Jefferies 2016 Healthcare Conference on June 8th at 11:00 a.m.
06/01/16 09:54 AMTrevena Inc (TRVN) Receives Buy Rating from FBR & Co. - Let Me Know About This - Trevena Inc (TRVN) Receives Buy Rating from FBR & Co.Let Me Know About ThisTrevena logo Trevena Inc (NASDAQ:TRVN)'s stock had its “buy” rating reaffirmed by equities research analysts at FBR & Co. in a note issued to investors on Wednesday. They currently have a $16.00 target price on the biopharmaceutical company's stock.Trevena Inc (NASDAQ:TRVN) Analyst ReviewRisers & FallersThe President & CEO of Trevena Inc (NASDAQ: TRVN) is Buying SharesAnalyst RatingsMaxine Gowen the President & CEO of Trevena Inc (NASDAQ:TRVN), Made a Purchase of 22084 Shares of the ...HNNFinance Dailyall 5 news articles »
05/31/16 07:19 PMShare Rating Focus on Trevena, Inc. (NASDAQ:TRVN) - HNN - Share Rating Focus on Trevena, Inc. (NASDAQ:TRVN)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.13 on shares of Trevena, Inc. (NASDAQ:TRVN). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number is ...and more »
05/31/16 07:19 PMMaxine Gowen the President & CEO of Trevena Inc (NASDAQ:TRVN), Made a Purchase of 22084 Shares of the ... - HNN - Maxine Gowen the President & CEO of Trevena Inc (NASDAQ:TRVN), Made a Purchase of 22084 Shares of the ...HNNA few days ago, an insider trading purchase was made. Maxine Gowen, the President & CEO and an insider of Trevena Inc purchased a total of 22,084 shares of Trevena Inc, worth precisely $157,275 U.S. Dollars, at $7.1 per share at the time of the purchase.Insider Activity - Trevena, Inc. (NASDAQ:TRVN)Finance Dailyall 2 news articles »
05/24/16 01:42 PMAfter Last Week What Do Analysts Think Of Trevena Inc (NASDAQ:TRVN) - Share Trading News - After Last Week What Do Analysts Think Of Trevena Inc (NASDAQ:TRVN)Share Trading News03/05/2014 – Zacks began new coverage on Trevena Inc giving the company a “hold” rating. The share price of Trevena Inc (NASDAQ:TRVN) was up +5.38% during the last trading session, with a day high of 6.91. 489074 shares were traded on Trevena Inc's ...Trevena Incorporated (NASDAQ:TRVN) Shorted Shares Decreased By 3.4%Wall Street Hints and Newsall 2 news articles »
05/24/16 01:42 PMHold Calls Count For Trevena, Inc. (NASDAQ:TRVN) At 0 - Stocks Daily - Hold Calls Count For Trevena, Inc. (NASDAQ:TRVN) At 0Stocks DailyBuy calls count on Trevena, Inc. (NASDAQ:TRVN)'s stock stands at 1 while Sell recommendations is 0. Hold recommendation is 0. Trevena, Inc. (NASDAQ:TRVN) has a total of 7 Strong Buy recommendations and 0 Strong Sell advises as of 2016-05-22.and more »
05/20/16 01:27 PMLatest Analyst Ratings For Trevena Inc (NASDAQ:TRVN) - Share Trading News - Share Trading NewsLatest Analyst Ratings For Trevena Inc (NASDAQ:TRVN)Share Trading News05/17/2016 – Trevena Inc had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 16 price target on the stock. 03/02/2016 – WallachBeth Capital began new coverage on Trevena Inc giving the company a “buy” rating.Trevena, Inc. (NASDAQ:TRVN) Hovering Around $6.56Investor NewswireTrevena Inc (NASDAQ:TRVN) Earnings per Share overviewNews OracleAnalysts Have Conflicting Sentiments on These Healthcare Companies: Trevena Inc. (NASDAQ: TRVN), Immune ...Markets.coMarket Digest -The Postall 8 news articles »
05/20/16 01:27 PMTop News: Atlas Resource Partners, L.P. (NYSE:ARP), Trevena, Inc. (NASDAQ:TRVN), Elbit Systems Ltd. (NASDAQ ... - KC Register - Top News: Atlas Resource Partners, L.P. (NYSE:ARP), Trevena, Inc. (NASDAQ:TRVN), Elbit Systems Ltd. (NASDAQ ...KC RegisterOn 16 May, Trevena, Inc. (NASDAQ:TRVN) announced that the company's TRV027 failed to meet either the primary or secondary endpoints in the Phase 2b BLAST-AHF study in acute heart failure (AHF). The company expects to focus its efforts on its lead ...and more »
05/20/16 01:27 PMRevenue Update on Trevena Inc(NASDAQ:TRVN) - Trade Calls - Revenue Update on Trevena Inc(NASDAQ:TRVN)Trade CallsTrevena Inc(NASDAQ:TRVN) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 5, 2016. Company reported revenue of $1.88M. Analysts estimated a revenue of $1.84M. Earnings per share were ...
05/19/16 07:03 PMETF’s with exposure to Trevena, Inc. : May 20, 2016 -
05/19/16 08:06 AMTREVENA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/18/16 01:46 PMSetbacks Still Outweigh Successes In Heart Failure - Seeking Alpha - Setbacks Still Outweigh Successes In Heart FailureSeeking AlphaYesterday's failure of Trevena's (NASDAQ:TRVN) TRV027 to meet either its primary or secondary endpoints in the Phase IIb Blast-AHF study marks another disappointment for a promising project in the challenging field of heart failure. Trevena has not yet ...
05/18/16 01:46 PMTrevena, Inc. (NASDAQ:TRVN) Hovering Around $6.56 - Investor Newswire - Share Trading NewsTrevena, Inc. (NASDAQ:TRVN) Hovering Around $6.56Investor NewswireOn performing technical analysis of Trevena, Inc. (NASDAQ:TRVN) stock, it is noted that the stock is $-1.33 points away -16.28% from its fifty-day MA of $8.18. It is $-2.17 or -24.04% away $9.02, the 200-day MA (Moving Average) of stock. Also, the ...Latest Analyst Ratings For Trevena Inc (NASDAQ:TRVN)Share Trading NewsTrevena Inc (TRVN) is Reiterated by Needham to Buy, Lowers Price Target to $ 11Market DigestTrevena Incorporated (NASDAQ:TRVN) Short Interest Decreased By 3.4%The Postall 8 news articles »
05/17/16 03:25 PMTrevena, Inc. :TRVN-US: Earnings Analysis: Q1, 2016 By the Numbers -

Social

About Trevena

Trevena logoTrevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TRVN
  • CUSIP:
Key Metrics:
  • Previous Close: $6.51
  • 50 Day Moving Average: $6.65
  • 200 Day Moving Average: $7.60
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $341.74M
  • Beta: -0.62
  • Current Year EPS Consensus Estimate: $-1.32 EPS
  • Next Year EPS Consensus Estimate: $-1.44 EPS
Additional Links:
Trevena (NASDAQ:TRVN) Chart for Tuesday, July, 26, 2016